1. US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies submitted in NDAs or INDs — general considerations. Rockville, MD: Food and Drug Administration I; 2014.
2. Use CfMPfH. Guideline on the investigation of bioequivalence. London: Agency EM; 2010.
3. An H. H-Likelihood Approach for Clinical Pharmacology Data [Doctor of Philosophy]. Seoul: Department of Statistics, Seoul National University; 2020.
4. Bioequivalence; Its History, Practice, and Future